Manufacturers report positive outcomes for lenacapavir for multi-drug resistant HIV-1 infection in Phase 2/3 CAPELLA trial

In trial, 73% patients achieved an undetectable viral load in maintenance period of trial with this investigational subcutaneous long-acting HIV-1 capsid inhibitor in combination with optimised background regimen, building on positive primary endpoint results announced previously

Source:

Biospace Inc.